Ian Taylor
YOU?
Author Swipe
View article: A process inspired by fractals for embedding digital codes into additively manufactured components for supply chain security
A process inspired by fractals for embedding digital codes into additively manufactured components for supply chain security Open
This study describes procedures for embedding digital information into additively manufactured components as well as procedures for readout and tensile testing. Embedded digital codes were printed inside ASTM E8/E8M dumbbells using Direct …
View article: Modeling Net Primary Productivity in a Cretaceous Terrestrial Ecosystem: A Probabilistic Approach
Modeling Net Primary Productivity in a Cretaceous Terrestrial Ecosystem: A Probabilistic Approach Open
View article: Publisher Correction: Transverse emittance reduction in muon beams by ionization cooling
Publisher Correction: Transverse emittance reduction in muon beams by ionization cooling Open
Accelerated muon beams have been considered for the next-generation studies of high-energy lepton–antilepton collisions and neutrino oscillations. However, high-brightness muon beams have not yet been produced. The main challenge for muon …
View article: Transverse emittance reduction in muon beams by ionization cooling
Transverse emittance reduction in muon beams by ionization cooling Open
View article: Incorporating patient and public involvement (PPI) at the design stage of an early career physiotherapy researcher's funding application: A co-produced reflective case report
Incorporating patient and public involvement (PPI) at the design stage of an early career physiotherapy researcher's funding application: A co-produced reflective case report Open
Aim
\nPatient and public involvement (PPI) in health and social care research is a requirement of nationally peer reviewed funders and the National Institute for Health Research (NIHR), including research grant applications. The United Kin…
View article: Key parameters linking cyber-physical trust anchors with embedded internet of things systems
Key parameters linking cyber-physical trust anchors with embedded internet of things systems Open
Integration of the Internet of Things (IoT) in the automotive industry has brought benefits as well as security challenges. Significant benefits include enhanced passenger safety and more comprehensive vehicle performance diagnostics. Howe…
View article: Transverse Emittance Reduction in Muon Beams by Ionization Cooling
Transverse Emittance Reduction in Muon Beams by Ionization Cooling Open
Accelerated muon beams have been considered for next-generation studies of high-energy lepton-antilepton collisions and neutrino oscillations. However, high-brightness muon beams have not yet been produced. The main challenge for muon acce…
View article: Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 45K, Dacomitinib response is associated with the total HER2 protein levels in HER2-amplified cell lines.
View article: Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 60K, Effect of dacomitinib on apoptosis in BT-474 and SK-BR-3 parental lines and lines resistant to trastuzumab and lapatinib.
View article: Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 55K.
View article: Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 60K, Effect of dacomitinib on apoptosis in BT-474 and SK-BR-3 parental lines and lines resistant to trastuzumab and lapatinib.
View article: Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 50K, Effect of dacomitinib on cell cycle in BT-474 and SK-BR-3 parental lines and lines resistant to trastuzumab and lapatinib.
View article: Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 77K, Comparison of the effect of dacomitinib at 48 hrs and 5 days on cell cycle and apoptosis in BT-474 and SK-BR-3 lines.
View article: Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 58K.
View article: Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 68K, Quantification of proteins from Western blots in Figure 3 by densitometry using ImageJ software.
View article: Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 58K.
View article: Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 77K, Comparison of the effect of dacomitinib at 48 hrs and 5 days on cell cycle and apoptosis in BT-474 and SK-BR-3 lines.
View article: Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 45K, Dacomitinib response is associated with the total HER2 protein levels in HER2-amplified cell lines.
View article: Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 75K, Dacomitinib response is marginally inversely correlated with relative HER3 mRNA levels.
View article: Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for HER2-amplified breast cancer, but a significant number of patien…
View article: Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for HER2-amplified breast cancer, but a significant number of patien…
View article: Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 50K, Effect of dacomitinib on cell cycle in BT-474 and SK-BR-3 parental lines and lines resistant to trastuzumab and lapatinib.
View article: Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 66K, Quantification of proteins from Western blots in Supplementary Figure S7 by densitometry using ImageJ software.
View article: Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 55K.
View article: Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 66K, Quantification of proteins from Western blots in Supplementary Figure S7 by densitometry using ImageJ software.
View article: Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 60K, Dacomitinib response is associated with relative HER2 mRNA levels.
View article: Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 68K, Quantification of proteins from Western blots in Figure 3 by densitometry using ImageJ software.
View article: Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 247K, The effects of dacomitinib on protein expression in lines resistant to trastuzumab and lapatinib.
View article: Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 60K, Dacomitinib response is associated with relative HER2 mRNA levels.
View article: Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Open
PDF file, 75K, Dacomitinib response is marginally inversely correlated with relative HER3 mRNA levels.